

FOR IMMEDIATE RELEASE

For More Information Contact:

Michael Schmainda
Imaging Biometrics, LLC
(262) 439-8252 • mike@imagingbiometrics.com



Standardized rCBV - A Reproducible Imaging Biomarker

For Immediate Release

June 24, 2015

Elm Grove, WI – Imaging Biometrics®, LLC (IB), a biotechnology company specializing in the development of software solutions for advanced visualization and analytics, announces the results of a study that underscores the accuracy and reproducibility of an important imaging biomarker in the treatment of brain cancer. The study, “Repeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma,” by Prah et al. from the Medical College of Wisconsin, has been published in the American Journal of Neuroradiology. The goal of the study was to determine the repeatability of relative cerebral blood volume (rCBV) measurements in newly-diagnosed glioblastoma multiforme, the most aggressive type of brain cancer, using several of the most common rCBV analysis techniques. The results show a clear difference among the repeatability of various methods, with standardized rCBV (sRCBV) proving the least variable. Moreover, because of its better accuracy, sRCBV requires fewer study participants to detect a desired change.

rCBV is a dynamic susceptibility contrast (DSC) magnetic resonance (MR) imaging parameter that is being increasingly used to evaluate brain tumors, stroke, and other neurological disorders. For patients with brain tumors, the information provided by rCBV measurements has been used to aid in grading the aggressiveness of tumors, monitoring tumor progression, and evaluating a tumor’s response to treatment. For rCBV to be adopted as the clinical standard of care, it must be both accurate and repeatable. Standardized rCBV measures, available exclusively within IB Neuro, give the best results in terms of each. Standardization is a patented image-intensity calibration process that compensates for variability inherent with MR imaging. Along with being the most accurate and repeatable, sRCBV makes MR images appear consistent across time and scanners and is fully automated in IB Neuro.

“The ability to characterize the repeatability of rCBV measures is important because it enables the determination of when a change in rCBV is an accurate representation of a tumor’s growth or response to treatment,” said Michael Schmainda, President and CEO of IB. “Without it, clinicians may require additional tests or more time to know, with confidence, that a given treatment protocol is effective,” Schmainda added.

FOR IMMEDIATE RELEASE

For More Information Contact:

Michael Schmainda
Imaging Biometrics, LLC
(262) 439-8252 • mike@imagingbiometrics.com



The study also highlights how the accuracy and repeatability of sRCBV can reduce the number of participants required to see a desired change. This has benefit in multi-center studies as well as in the development of new cancer fighting agents. “The faster drug companies can determine if a new cancer-fighting agent is working, the faster they can be made available for patients,” said Schmainda.

IB products are available as plug-ins into the aycan OsiriX PRO workstation. Together, IB and aycan Medical Systems are making advanced imaging available to clinicians in an automated and affordable manner.

About Imaging Biometrics™ LLC

Imaging Biometrics develops and provides visualization and analytical solutions enabling clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, and medical viewers. By design, IB's advanced visualization software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, LLC, visit www.imagingbiometrics.com.